Your browser doesn't support javascript.
loading
Review of Technological Challenges in Personalised Medicine and Early Diagnosis of Neurodegenerative Disorders.
Domínguez-Fernández, Celtia; Egiguren-Ortiz, June; Razquin, Jone; Gómez-Galán, Margarita; De Las Heras-García, Laura; Paredes-Rodríguez, Elena; Astigarraga, Egoitz; Miguélez, Cristina; Barreda-Gómez, Gabriel.
Afiliação
  • Domínguez-Fernández C; Research and Development Division, IMG Pharma Biotech, 48160 Derio, Spain.
  • Egiguren-Ortiz J; Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.
  • Razquin J; Research and Development Division, IMG Pharma Biotech, 48160 Derio, Spain.
  • Gómez-Galán M; Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.
  • De Las Heras-García L; Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.
  • Paredes-Rodríguez E; Neurodegenerative Diseases Group, Biocruces Bizkaia Health Research Institute, 48940 Barakaldo, Spain.
  • Astigarraga E; Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.
  • Miguélez C; Department of Pharmacology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, 48940 Leioa, Spain.
  • Barreda-Gómez G; Research and Development Division, IMG Pharma Biotech, 48160 Derio, Spain.
Int J Mol Sci ; 24(4)2023 Feb 07.
Article em En | MEDLINE | ID: mdl-36834733
ABSTRACT
Neurodegenerative disorders are characterised by progressive neuron loss in specific brain areas. The most common are Alzheimer's disease and Parkinson's disease; in both cases, diagnosis is based on clinical tests with limited capability to discriminate between similar neurodegenerative disorders and detect the early stages of the disease. It is common that by the time a patient is diagnosed with the disease, the level of neurodegeneration is already severe. Thus, it is critical to find new diagnostic methods that allow earlier and more accurate disease detection. This study reviews the methods available for the clinical diagnosis of neurodegenerative diseases and potentially interesting new technologies. Neuroimaging techniques are the most widely used in clinical practice, and new techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) have significantly improved the diagnosis quality. Identifying biomarkers in peripheral samples such as blood or cerebrospinal fluid is a major focus of the current research on neurodegenerative diseases. The discovery of good markers could allow preventive screening to identify early or asymptomatic stages of the neurodegenerative process. These methods, in combination with artificial intelligence, could contribute to the generation of predictive models that will help clinicians in the early diagnosis, stratification, and prognostic assessment of patients, leading to improvements in patient treatment and quality of life.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicina de Precisão / Doença de Alzheimer Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicina de Precisão / Doença de Alzheimer Tipo de estudo: Diagnostic_studies / Prognostic_studies / Screening_studies Limite: Humans Idioma: En Revista: Int J Mol Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Espanha